{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:42:32Z","timestamp":1792636952411,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2761,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1093\/annonc\/mdr435","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T01:36:38Z","timestamp":1318296998000},"page":"1341-1347","source":"Crossref","is-referenced-by-count":678,"title":["Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases"],"prefix":"10.1016","volume":"23","author":[{"given":"F.","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.J.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.H.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Senecal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Carri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr435_bb0010","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0015","article-title":"Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience","volume":"106","author":"Cafro","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdr435_bb0020","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdr435_bb0025","article-title":"The incidence of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma who receive biphosphonates depends on the type of biphosphonate","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdr435_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr435_bb0035","article-title":"Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw","volume":"106","author":"Pozzi","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdr435_bb0040","article-title":"Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid","volume":"106","author":"Tosi","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdr435_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdr435_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdr435_bb0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","article-title":"A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdr435_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0065","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0070","series-title":"CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw","author":"European Medicines Agency","year":"2011"},{"key":"10.1093\/annonc\/mdr435_bb0075","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18s","key":"10.1093\/annonc\/mdr435_bb0080","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1200\/jco.2006.24.18_suppl.8528","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy","volume":"24","author":"Hoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0085","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.joms.2007.03.021","article-title":"Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Herbozo","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","article-title":"Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases","volume":"42","author":"Bagan","year":"2006","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0095","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-010-0933-9","article-title":"Osteonecrosis of the jaw and bevacizumab therapy","volume":"122","author":"Van Poznak","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdr435_bb0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdr435_bb0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","article-title":"Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates","volume":"28","author":"King","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1093\/annonc\/mdr435_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejim.2006.10.008","article-title":"Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature","volume":"18","author":"Cavanna","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1093\/annonc\/mdr435_bb0120","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF03026321","article-title":"The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib","volume":"23","author":"Mashiba","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"10.1093\/annonc\/mdr435_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr435_bb0135","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0140","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0145","author":"Department of Health and Human Services, Food and Drug Administration, Oncologic Drugs Advisory Committee","year":"2011"},{"key":"10.1093\/annonc\/mdr435_bb0150","series-title":"Effect of Cancer on Quality of Life","first-page":"293","article-title":"Pain assessment in cancer","author":"Cleeland","year":"1991"},{"key":"10.1093\/annonc\/mdr435_bb0155","series-title":"Analysis of Clinical Trials Using SAS: A Practical Guide","author":"Dmitrienko","year":"2005"},{"key":"10.1093\/annonc\/mdr435_bb0160","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0165","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0170","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdr435_bb0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr435_bb0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdr435_bb0190","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdr435_bb0195","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1093\/annonc\/mdr435_bb0200","author":"American Dental Association","year":"2011","journal-title":"Report of the Council on Scientific Affairs: Dental Management of Patients Receiving Oral Bisphosphonate Therapy\u2014Expert Panel Recommendations"},{"key":"10.1093\/annonc\/mdr435_bb0205","doi-asserted-by":"crossref","first-page":"864","DOI":"10.14219\/jada.archive.2009.0280","article-title":"Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review","volume":"140","author":"Almazrooa","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"10.1093\/annonc\/mdr435_bb0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bjoms.2010.05.007","article-title":"Bisphosphonate osteonecrosis of the jaw\u2014a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention","volume":"49","author":"Patel","year":"2011","journal-title":"Br J Oral Maxillofac Surg"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/5\/1341\/13785868\/mdr435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T05:23:23Z","timestamp":1624425803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0923753419346952"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr435","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}